The MLR Review Process for Promotional Materials, Step by Step

Every piece of pharmaceutical promotional material, an email, a sales aid, a banner, a congress panel, moves through the same sequence of gates before it reaches a physician. That sequence is the MLR review process, and understanding it stage by stage is the difference between a piece that clears in two rounds and one that clears in twenty.

This is the full walkthrough: the five stages, who signs off at each, how long each takes, and the five reasons promotional materials keep looping back. (For the definition of the term itself, and what MLR stands for, start with what MLR review is.)

The MLR review process, step by step

Every company's workflow differs in the details, but almost all of them run the same five stages.

Stage 1: Create and submit

Marketing, or an external agency, drafts the asset and assembles the submission package. That package is not just the creative. It is the copy, the claims, the supporting references, and, critically, the link between each claim and the exact passage of the source that substantiates it.

The package is uploaded to a Life Sciences DAM (Digital Asset Management) platform, typically Veeva Vault PromoMats, Aprimo, or Vodori, with Salesforce's Life Sciences Cloud DAM module on the roadmap for the second half of 2026. Most delays are created here, not later: what you submit determines how many rounds follow.

Stage 2: Review

Each reviewer reads the piece independently and leaves comments. The three functions look for three different kinds of risk:

Medical verifies every claim against its cited source, and checks that the source actually supports the claim as worded.
Regulatory checks consistency with the approved label (the prescribing information) and the applicable promotional rules.
Legal checks liability, intellectual property, and contractual exposure.

This is where the flags go up, but it is rarely where the calendar goes.

Stage 3: Revise and resubmit

The creator addresses the comments and sends the piece back. This is the stage that consumes the timeline. A clean piece loops through it two or three times. A poorly prepared one loops ten or more, and each pass restarts the review clock for every function.

Stage 4: Approve and date

Once all reviewers sign off, the asset is approved, assigned an expiry date, and locked. The expiry date matters more than teams expect: it is what forces the piece back through review later, and an entire second wave of MLR work comes from re-certifying expiring assets rather than creating new ones.

Stage 5: Distribute

The approved, dated asset is released to the field or the channel. Any change after this point, even a single word, sends it back to stage 1.

Who signs off at each stage

Medical, legal, and regulatory reviewers each sign off in stage 2, and no piece advances until all three have. Who inside those functions carries the work varies widely: a 2024 promotional-review benchmark from Canopy found that when teams were asked who in Medical Affairs owns promotional review, 44% pointed to the medical director, 23% to medical information, and just 15% to a dedicated promotional-review function.

That distinction matters for the process, because a medical director is a bottleneck with a clinic and a leadership role attached. Teams that route routine medical review to a brand's medical-information lead, reserving senior sign-off for genuinely high-risk pieces, move materially faster. We break the ownership and accountability data down in who owns MLR review.

How long the MLR review process takes

Industry benchmarks put the average content approval cycle at roughly 21 days. That figure hides an enormous spread.

In a 2025 analysis of medical reviewers, the time to review a single promotional one-pager ranged from under an hour to more than five (N=192). The deciding factor was not length. It was quality: whether the claims had been pre-aligned, and whether the references actually supported them. The same one-page leave-behind is a ten-minute job or a lost weekend, depending entirely on who prepared it.

The cost lands on reviewers. In the Canopy data, roughly two out of three reviewers spend at least 15% of their working week on promotional review, and about one in three spend 25% or more.

Why promotional materials get sent back 10+ times

Ask anyone who has pushed a promotional piece through MLR review for their war story, and you will get a number. One agency lead we spoke with said the version they finally uploaded to Veeva was v35. Not version three, or version five. Thirty-five.

It is almost never one big failure. It is the same handful of small ones, compounding.

1. The submission was never review-ready

The strongest predictor of how many rounds a piece needs is the state it arrives in. When a draft lands without each claim linked and anchored to the exact line of its source, the reviewer cannot simply verify it. They have to reconstruct it, hunting through PDFs for the sentence that supports each claim. We dig into that failure mode in why your MLR process is broken before it starts.

2. Every audience needs its own wording, and every wording is its own review

The claim you make to a physician is not the claim you make to a pharmacist, and neither is what you are allowed to show a patient who has already been prescribed the product. Each of those is a separate piece of copy, with its own substantiation, and each one goes through review on its own.

Multiply one core message across three or four audiences and channels and you have not created one review job. You have created three or four, each able to loop independently.

3. A single word can reset the whole cycle

This is the one that makes creative teams despair. A legal reviewer asks to soften a single adjective, "clear" becomes "clearer," and because that word sits inside a claim, the claim has to be re-substantiated and the piece loops back through review. These late, tiny changes are normal rather than exceptional, and they often land at the very end of the process, after everyone thought the piece was done.

Claim drift works the same way in reverse: the quiet addition of a "unique" or a "first-line" that nobody flagged turns a previously approved claim into a new one that has to be re-reviewed. And the specifics invite scrutiny. Study parameters, the exact patient number, the comparator arm, the endpoint wording, are precisely the details a careful reviewer stops on, and precisely the ones a copywriter is tempted to round off.

4. The reviewers do not always agree, even with each other

MLR is not one gate. It is three (medical, legal, and regulatory), plus the marketing or agency team that wrote the piece, and they do not share a single definition of "approved." Marketing writes the ambitious claim; medical and regulatory have to make it defensible. That tension is healthy, but it is also rounds.

The most expensive version is internal. The senior medical signatory sometimes overrules feedback their own team already gave, so a change made in round four to satisfy one reviewer gets reversed in round eight by another. When 52% of practitioners say accountability for MLR should sit with a cross-functional team rather than any one person, this is the flip side: shared accountability without shared judgment means more voices, and more rounds.

5. Nobody remembers why the last version was rejected

Agencies and brand teams turn over. The person who learned, the hard way, that a particular phrasing would never clear review is gone next year, and the lesson left with them. Approved claims are not always formalized in the claims library, and external agencies frequently cannot see the full library anyway, so they rebuild from scratch, sometimes re-submitting wording that was already rejected once.

Without a durable record of what was rejected and why, the cycle does not just repeat inside one project. It repeats across every project that follows.

How to make the first round count

You cannot legislate away disagreement, and you would not want to; that friction is doing real compliance work. But most of the rounds above are not disagreement. They are avoidable rework, and three habits remove most of it:

Arrive review-ready. Every claim linked and anchored to the exact line of its source, so the first round is verification, not reconstruction. Our MLR review readiness checklist is the eight-point test to run before you submit. (Even formatting the reference cleanly helps; our free AMA citation generator turns a PubMed record into a clean citation in one paste.)
Keep a living claim library, with its rejections. Lock approved claims to their references so they are reused, and record what was rejected and why so it is not re-submitted.
Pre-align before you submit. Get medical and legal to weigh in on the wording before it is baked into a designed, laid-out piece, so the word-level changes happen on a draft, not on version 30.

When volume spikes at launch and the process cannot absorb it, the levers change; we cover those in scaling MLR review.

This is the gap PharmaText.ai was built to close. Our Precision Traceability engine anchors every claim to its source as the content is drafted, so what reaches MLR is already linked, already anchored, and ready to be verified instead of reconstructed. It will not get you to version one. But it can get you out of version 35.

MLR review process FAQ

What are the stages of the MLR review process? Five: create and submit, review by medical/legal/regulatory, revise and resubmit, approve and date, then distribute. Stage 3, revise and resubmit, is the stage that consumes the timeline, because it can repeat many times before every function signs off.

How long does the MLR review process take? The average content approval cycle runs around 21 days, but the spread is enormous. Reviewing a single promotional one-pager has been measured at anywhere from under an hour to more than five hours, and the deciding factor is how review-ready the submission was, not how long the piece is.

Why do promotional materials get sent back so many times? Five recurring causes: the submission was not review-ready, each audience variant is its own review, a single word change re-opens a claim, the three reviewing functions disagree with each other, and nobody has a durable record of what was rejected last time and why.

What is the difference between MLR review and the MLR review process? MLR review is the gate itself, the medical, legal, and regulatory sign-off that promotional content must clear. The MLR review process is the sequence of stages that content moves through to get there, from submission to distribution.

Who approves promotional materials in pharma? Medical, legal, and regulatory reviewers all sign off. In many companies the medical director is the primary medical reviewer, though accountability is increasingly held by a cross-functional team rather than any single person.

Sources: promotional-review time data from the Medical Affairs workload overview by Maaike Addicks, medicalaffairs.nl (2025); reviewer workload and ownership data presented at a 2024 industry webinar by Canopy; MLR accountability polling from a 2024 industry webinar by Impatient Health.